511 related articles for article (PubMed ID: 19900193)
1. Incretin-based therapies: therapeutic rationale and pharmacological promise for type 2 diabetes.
Wick A; Newlin K
J Am Acad Nurse Pract; 2009 Nov; 21 Suppl 1():623-30. PubMed ID: 19900193
[TBL] [Abstract][Full Text] [Related]
2. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
3. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
4. Differentiating incretin-based therapies for population-based health care.
Calabrese D
Am J Manag Care; 2011 Mar; 17(2 Suppl):S52-8. PubMed ID: 21517657
[TBL] [Abstract][Full Text] [Related]
5. New developments in incretin-based therapies: the current state of the field.
Robertson C
J Am Acad Nurse Pract; 2009 Nov; 21 Suppl 1():631-41. PubMed ID: 19900194
[TBL] [Abstract][Full Text] [Related]
6. Is there a place for incretin therapies in obesity and prediabetes?
Holst JJ; Deacon CF
Trends Endocrinol Metab; 2013 Mar; 24(3):145-52. PubMed ID: 23415157
[TBL] [Abstract][Full Text] [Related]
7. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
8. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
9. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Vergès B; Bonnard C; Renard E
Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
[TBL] [Abstract][Full Text] [Related]
10. Incretin-based therapies: can we achieve glycemic control and cardioprotection?
Angeli FS; Shannon RP
J Endocrinol; 2014 Apr; 221(1):T17-30. PubMed ID: 23926280
[TBL] [Abstract][Full Text] [Related]
11. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Bourdel-Marchasson I; Schweizer A; Dejager S
Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
[TBL] [Abstract][Full Text] [Related]
12. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
[TBL] [Abstract][Full Text] [Related]
13. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
Gallwitz B
Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
[TBL] [Abstract][Full Text] [Related]
14. Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.
Dejager S; Schweizer A
Hosp Pract (1995); 2012 Apr; 40(2):7-21. PubMed ID: 22615074
[TBL] [Abstract][Full Text] [Related]
15. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
Freeman JS
Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298
[TBL] [Abstract][Full Text] [Related]
16. The incretin system and its role in type 2 diabetes mellitus.
Holst JJ; Vilsbøll T; Deacon CF
Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
[TBL] [Abstract][Full Text] [Related]
17. Incretins: their physiology and application in the treatment of diabetes mellitus.
Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
[TBL] [Abstract][Full Text] [Related]
18. Complementing insulin therapy to achieve glycemic control.
Barnett AH
Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
[TBL] [Abstract][Full Text] [Related]
19. Optimizing outcomes with incretin-based therapies: practical information for nurse practitioners to share with patients.
Fleury-Milfort E
J Am Acad Nurse Pract; 2009 Nov; 21 Suppl 1():642-50. PubMed ID: 19900195
[TBL] [Abstract][Full Text] [Related]
20. Incretin-based therapies and cardiovascular risk.
Mannucci E; Dicembrini I
Curr Med Res Opin; 2012 May; 28(5):715-21. PubMed ID: 22439700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
